Variability of parvovirus B19 genotype 2 in plasma products with different compositions in the inactivation sensitivity by liquid-heating
M. Tsujikawa
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorH. Nishigaki
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorM. Yoshikawa
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorR. Furuki
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorK. Takahashi
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorJ. Adan-Kubo
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorY. Shimamura
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorT. Urayama
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorS. Hattori
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorK. Sakai
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorM. Yunoki
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorK. Ikuta
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorM. Tsujikawa
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorH. Nishigaki
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorM. Yoshikawa
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorR. Furuki
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorK. Takahashi
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorJ. Adan-Kubo
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorY. Shimamura
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorT. Urayama
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorS. Hattori
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorK. Sakai
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Search for more papers by this authorM. Yunoki
Osaka Research Laboratory, Research and Development Division, Benesis Corporation, Osaka, Japan
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorK. Ikuta
Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Search for more papers by this authorAbstract
Background and Objectives Our previous report showed that parvovirus B19 genotype 1 in different solutions derived from plasma preparations showed different heat-sensitivity patterns during liquid-heating. In this study, we similarly examined B19 genotype 2.
Materials and Methods Two plasma samples one containing B19 genotype 1 and the other genotype 2 DNA were used. Four process samples collected immediately before the heat treatment step in the manufacture of albumin, immunoglobulin, haptoglobin and antithrombin preparations were spiked with B19 and subsequently treated at 60°C for 10 h. A low pH immunoglobulin solution was also spiked with B19 and treated at room temperature for 14 days. Infectivity was then measured.
Results B19 genotype 2, similar to genotype 1, showed three patterns of inactivation: (i) a rapid inactivation in the albumin and immunoglobulin preparations, (ii) a slow inactivation in the haptoglobin preparation and (iii) only limited inactivation in the antithrombin preparation. Its sensitivity in the low pH immunoglobulin solutions also resembled that of genotype 1.
Conclusion Both genotypes 1 and 2 of B19 varied in sensitivity to liquid-heating and low pH among different plasma preparations.
References
- 1 Erdman DD, Durigon EL, Wang Qi-Y, et al. : Genetic diversity of human parvovirus B19: sequence analysis of the VP1/VP2 gene from multiple isolates. J Gen Virol 1996; 77: 2767–2774
- 2 Nguyen QT, Sifer C, Schneider V, et al. : Novel human erythrovirus associated with transient aplastic anemia. J Clin Microbiol 1999; 37: 2483–2487
- 3 Hokynar K, Söderlund-Venemo M, Pesonen M, et al. : A new parvovirus genotype persistent in human skin. Virology 2002; 302: 224–228
- 4 Nguyen QT, Wong S, Heegaard ED, et al. : Identification and characterization of a second novel human erythrovirus variant, A6. Virology 2002; 301: 374–380
- 5 Hokynar K, Norja P, Hedman K, et al. : Tissue persistence and prevalence of B19 virus types 1-3. Future Virol 2007; 2: 377–388
- 6 Servant A, Laperche S, Lallemand F, et al. : Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76: 9124–9134
- 7 Baylis SA: Standardization of nucleic acid amplification technique (NAT)-based assays for different genotypes of parvovirus B19: a meeting summary. Vox Sang 2008; 94: 74–80
- 8 Ozawa K, Young N: Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell culture. J Virol 1987; 61: 2627–2630
- 9 Prowse C, Ludlam CA, Yap PL: Human parvovirus B19 and blood products. Vox Sang 1997; 72: 1–10
- 10 Schmidt I, Blümel J, Seitz H, et al. : Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001; 81: 228–235
- 11 Schneider B, Becker M, Brackmann H-H, et al. : Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb Haemost 2004; 92: 838–845
- 12 Blümel J, Schmidt I, Willkommen H, et al. : Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42: 1011–1018
- 13 Yunoki M, Tsujikawa M, Urayama T, et al. : Heat sensitivity of human pavovirus B19. Vox Sang 2003; 84: 164–169
- 14 Hattori S, Yunoki M, Tsujikawa M, et al. : Variability of parvovirus B19 to inactivation by liquid heating in plasma products. Vox Sang 2007; 92: 121–124
- 15 Yunoki M, Urayama T, Tsujikawa M, et al. : Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations. Br J Haematol 2004; 128: 401–404
- 16 Blümel J, Eis-Hübinger AM, Stühler A, et al. : Characterization of parvovirus B19 genotype 2 in KU812Ep6 cells. J Virol 2005; 79: 14197–14206
- 17 Berting A, Modrof J, Unger U, et al. : Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates. Transfusion 2008; 48: 1220–1226
- 18 Prikhod’ko GG, Vasilyeva I, Reyes H, et al. : Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion 2005; 45: 1011–1019
- 19 Tullis GE, Burger LR, Pintel DJ: The minor capsid protein VP1 of the autonomous parvovirus minute virus of mice is dispensable for encapsidation of progeny single-stranded DNA but is required for infectivity. J Virol 1993; 67: 131–141
- 20 The European Agency for the Evaluation of Medical Products/Committee for Proprietary Medical Products (CPMP) Biotechnology Working Party, Ad-Hoc Working Group on Blood Products: Guideline on Assessing the Risk for Virus Transmission – New Chapter 6 of the Note for Guidance on Plasma-derived Medicinal Products (CPMP/BWP/296/95). CPMP/BWP/5180/03. 2004. Available from: http://www.emea.eu.int/index/indexh1.htm
- 21 Abe H, Sugawara H, Hirayama J, et al. : Removal of parvovirus B19 from hemoglobin solution by nanofltration. Artif Cells blood substit Immobil Biotechnol 2000; 28: 375–383
- 22 Mani B, Gerber M, Lieby P, et al. : Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses. Transfusion 2007; 47: 1765–1774
- 23 Ros C, Baltzer C, Mani B, et al. : Parvovirus uncoating in vitro reveals a mechanism of DNA release without capsid disassembly and striking differences in encapsidated DNA stability. Virology 2006; 345: 137–147
- 24 Ros C, Gerber M, Kempf C: Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol 2006; 80: 12017–12024
- 25 Cotmore SF, D’Abramo AM, Ticknor CM, et al. : Controlled conformational transitions in the MVM virion expose the VP1 N-terminus and viral genome without particle disassembly. J Virol 1999; 254: 169–181
- 26 Modrof L, Berting A, Tille B, et al. : Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion 2008; 48: 178–186
- 27 Liefeldt L, Plentz A, Klempa B, et al. : Recurrent high level parvovirus B19/genotype2 viremia in a renal transplant recipient analyzed by real-time PCR for simultaneous detection of genotypes 1 to 3. J Med Virol 2005; 75: 161–169
Citing Literature
